The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts Meeting Abstract
| Authors: | Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; Blouin, W.; Hancock, H.; Ganesan, N.; Galasso, N.; Marzouk, E.; Bahgat, A.; Jester, H.; Fong, S.; Butt, A.; Dogan, A.; Kim, Y. H.; Weinstock, D. M. |
| Abstract Title: | The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837602061 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 683 -- Source: Wos |
